b-CAPSA I XXXX , type b, capsular polysaccharide vaccine safety.

@entity1 @entity5143 @entity327 @entity410
The b-CAPSA I capsular polysaccharide vaccine for @entity327 type b was given to 87,541 @entity1 2 through 5 years of age in the Kaiser Permanente Medical Care Program, and the @entity1 were then followed using a multiple modality surveillance. Phase 1 consisted of 24-hour recall of immediate side effects which were recorded on questionnaires given to families of 13,500 @entity1 . Local side effects were found to be uncommon: 2.3% had a temperature of greater than or equal to 38.3 degrees C (greater than or equal to 101 degrees F); 4.8% had local erythema, 2.9% local swelling, and 12.6% local tenderness; two @entity1 had wheezing shortly after immunization. In Phase 2, 30 days after immunization, questionnaires were mailed to parents of all 87,541 @entity1 , who were asked to respond to questions about illnesses and health care. Phase 3 consisted of active surveillance of @entity1 health care use by physicians and nurses during the 30 days after immunization. During the 30-day reporting periods, there were 40 hospitalizations, including one for wheezing and one for febrile @entity410 . Of the 40 hospitalizations, only the one for wheezing was believed by the admitting physician to be probably associated with vaccine administration. Three @entity1 had @entity410 within 30 days of immunization. None of the @entity410 was believed by the reporting physician to be associated with immunization. Adverse effects of the vaccine were mild, limited to local reactions and occasional temperature elevation; @entity5143 after immunization occurred rarely.
